



## Paclitaxel



Number of patients at risk

|            |    |    |    |    |    |   |
|------------|----|----|----|----|----|---|
| Increased  | 21 | 21 | 20 | 17 | 10 | 3 |
| Maintained | 20 | 20 | 16 | 16 | 11 | 2 |
| Decreased  | 16 | 15 | 10 | 6  | 4  |   |

## Docetaxel



Number of patients at risk

|            |    |    |    |   |   |   |
|------------|----|----|----|---|---|---|
| Increased  | 27 | 26 | 19 | 9 | 3 | 1 |
| Maintained | 33 | 29 | 21 | 9 | 4 |   |
| Decreased  | 24 | 19 | 8  | 5 | 2 |   |

Fig. S6. Kaplan–Meier curves for DFS according to changes in SMI (increased, maintained, and decreased) in patients treated with paclitaxel (left) and docetaxel (right).

DFS: Disease-free survival, SMI: Skeletal muscle index